Status:
COMPLETED
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
Lead Sponsor:
University of Iowa
Collaborating Sponsors:
Mayo Clinic
Pfizer
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
* CpG has the potential to stimulate the immune system * this study will evaluate the safety of CpG given sub-q or IV * purpose is to measure biological changes in CLL cells after receiving CpG
Eligibility Criteria
Inclusion
- Diagnosis of CLL
- CLL previously treated
- Hemoglobin \>/= 10
- Platelets \>/= 50,000
- Neutrophils \>= 1,000 -
Exclusion
- patients with brain mets
- patients with autoimmune disease
- patients on corticosteroids or immunosuppressants
- patients with uncontrolled intercurrent illness
- pregnant women
- HIV patients receiving combination anti-retroviral therapy
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00233506
Start Date
July 1 2004
End Date
June 1 2011
Last Update
February 6 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa
Iowa City, Iowa, United States, 52242
2
Mayo Clinic
Rochester, Minnesota, United States, 55905